PT  - JOURNAL ARTICLE
AU  - Deng, Isaac Bul
AU  - Follett, Jordan
AU  - Bu, Mengfei
AU  - Farrer, Matthew J.
TI  - DNAJC12 in monoamine metabolism, neurodevelopment and neurodegeneration
AID  - 10.1101/2023.06.22.23291747
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.22.23291747
4099  - http://medrxiv.org/content/early/2023/06/23/2023.06.22.23291747.short
4100  - http://medrxiv.org/content/early/2023/06/23/2023.06.22.23291747.full
AB  - Recent studies show that mutations in DNAJC12, a co-chaperone for monoamine synthesis may cause mild hyperphenylalaninemia with infantile dystonia, young-onset parkinsonism, developmental delay and cognitive deficits. To this end, DNAJC12 gene has been included in newborn screening, most revealingly in Spain, and those results are a testament to the importance of early diagnosis and treatment in combating human diseases. However, practitioners may be unaware of these advances and it is probable that many patients, especially adults, have yet to receive molecular testing for DNAJC12. Therefore, this review summarizes genotype-phenotype relationships and treatment paradigms for patients with DNAJC12 mutations. It provides an overview of the structure of DNAJC12 protein, known mutations, domains and binding partners, and elaborates on its role in monoamine synthesis, disease etiology and pathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.